983-984
Editorial Commentary
Drug-related risks
Ulrich Klotz
985-989
Clinical Trial
Long-term changes in management following n-of-1 trials of stimulants in attention-deficit/hyperactivity disorder
C. Jane Nikles, Geoffrey K. Mitchell, Chris B. Del Mar, Norma McNairn and Alexandra Clavarino
991-996
Pharmacogenetics
Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome
Daiji Kato, Chiaki Kawanishi, Ikuko Kishida, Taku Furuno and Kyoko Suzuki, et al.
997-1005
Pharmacogenetics
Vitamin D receptor haplotypes protect against development of colorectal cancer
Jana Flügge, Solveigh Krusekopf, Mark Goldammer, Elena Osswald and Werner Terhalle, et al.
1007-1009
Pharmacodynamics
Acute myocarditis after massive phenelzine overdose
W. Stephen Waring and William A. H. Wallace
1011-1017
Pharmacodynamics
Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study
Réginald Hulhoven, Dominique Rosillon, Michel Letiexhe, Marie-Anne Meeus and Agnès Daoust, et al.
1019-1029
Pharmacokinetics and Disposition
Population pharmacokinetic analysisof lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART
Xavière Panhard, Mayeule Legrand, Anne-Marie Taburet, Bertrand Diquet and Cécile Goujard, et al.
1031-1038
Pharmacokinetics and Disposition
Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration
Takenori Niioka, Tsukasa Uno, Katsuyoshi Sugimoto, Kazunobu Sugawara and Makoto Hayakari, et al.
1039-1044
Pharmacokinetics and Disposition
Open AccessEvaluation of limited sampling strategies for tacrolimus
Robert A. M. Op den Buijsch, Afke van de Plas, Leo M. L. Stolk, Maarten H. L. Christiaans and Johannes P. van Hooff, et al.
1045-1054
Pharmacokinetics and Disposition
Pharmacokinetic–pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans
Helmut Schmidt and Jörn Lötsch
1055-1061
Pharmacoepidemiology and Prescription
Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study
Joerg Hasford, Detlef Schröder-Bernhardi, Marietta Rottenkolber, Karel Kostev and Gerhard Dietlein
1063-1067
Pharmacoepidemiology and Prescription
Attitudes toward psychiatric drug treatment: the experience of being treated
Carlos De las Cuevas and Emilio J. Sanz
1069-1074
Pharmacoepidemiology and Prescription
High concordance between self-reported medication and official prescription database information
Jari Haukka, Jaana Suvisaari, Annamari Tuulio-Henriksson and Jouko Lönnqvist
1075-1083
Pharmacoepidemiology and Prescription
Recognition and management of potential drug–drug interactions in patients on internal medicine wards
Priska Vonbach, André Dubied, Jürg H. Beer and Stephan Krähenbühl
1085-1094
Pharmacoepidemiology and Prescription
Why healthy subjects volunteer for phase I studies and how they perceive their participation?
Luis Almeida, Benedita Azevedo, Teresa Nunes, Manuel Vaz-da-Silva and Patrício Soares-da-Silva
1095
Erratum
Potential drug interactions during a three-decade study period: a cross-sectional study of a prescription register
Emelie Åstrand, Bengt Åstrand, Karolina Antonov and Göran Petersson